And it is paid by the signing of the bookWe already had the intention to privatizeTHE SOVEREIGN INTERESTby Frédéric LordonEdYoung people read less than their elders 45Then each President will bet on his personal equation This is not the business tax reform it addedInvolvement of the State in either activityAnd at a time when the market is very competitive17 or below half the rate for the Japan 0The Elysee and Matignon supported the approachThis is not all the days that a public laboratory of biology signs a research partnership of several million euros with one of the first industrial pharmacy. Yet this is what comes to the lab I-Stem, located in Evry, and specializing in the exploration of the therapeutic potential of stem cells in the treatment of rare genetic diseases. This laboratory has indeed just an agreement with the Swiss group Roche. He will receive 7.5 million to initiate two years rock teams, who will come to Evry, its Protocol for the screening of molecules on (read opposite) human embryonic stem cells.
The Swiss group wishes to use the technology developed at I-Stem to identify new molecules able to combat the degenerative diseases of central nervous system, such as Alzheimer's or Parkinson's disease. A number of data from the scientific literature suggests that some treatments used for example to treat depression should their effectiveness not only their antidepressant effect but also their ability to promote a certain neuronal recovery by stimulating still present stem cell differentiation in the adult brain. The idea of rock, which has a library of 1.4 million of molecules, is therefore to test a large number of molecules to see if some of them do not stimulate the growth and differentiation of neural stem cells, which would stop the mechanism of degeneration.
A new breath
"Or I-Stem, which brings together a mixed Inserm-University of Evry unit and a unit of research funded by the French Association against myopathies (via the Telethon) has developed for its own needs for research in disease of Huntington, a rare neurodegenerative disease, a protocol for differentiation of the embryonic stem cells into neuronal cells, adapted to the machines used for molecules to high throughput screening." "Hence the interest of rock for our technology", explains Marc Peschanski, Director of I-Stem.
In rock, it is recognized that this agreement is intended to give a new breath to pharmaceutical research that tramples underfoot for several years. "We compared the global expertise of the centres developing innovative approaches on stem cells," said Lee Babiss, responsible for the research of the laboratory in Basel. The first concrete results of this non-exclusive collaboration are expected in a year. If they are successful this approach will be extended to other therapeutic areas covered by the manufacturer. Longer term, the Group also plans to become a player in the field of cell therapies, if this option is proving effective and ethically acceptable.
But academic research also is his account, reflecting to a certain professionalization in its recovery. "As soon as he comes to work on a large scale and high speed, work with an industrial quality of rock can be only profitable", said André Syrota, CEO of Inserm. Not to mention that "the high-throughput techniques to generate a type of knowledge that can be obtained by other means." This collaboration should therefore give rise to numerous publications. "This type of partnership enables a real cross-fertilization," he continued. "It reflects also the ongoing professionalization in upgrading research in life sciences and health".
